4//SEC Filing
Eydelman Mikhail 4
Accession 0001649094-25-000004
CIK 0001649094other
Filed
Jan 6, 7:00 PM ET
Accepted
Jan 7, 4:33 PM ET
Size
12.5 KB
Accession
0001649094-25-000004
Insider Transaction Report
Form 4
Vaxcyte, Inc.PCVX
Eydelman Mikhail
SVP, GEN COUNSEL & CORP SEC
Transactions
- Sale
Common Stock
2025-01-06$84.86/sh−954$80,953→ 32,268 total - Sale
Common Stock
2025-01-06$85.73/sh−3,921$336,155→ 28,347 total - Sale
Common Stock
2025-01-06$86.52/sh−125$10,815→ 28,222 total - Exercise/Conversion
Stock Option (right to buy)
2025-01-06−5,000→ 154,497 totalExercise: $21.41Exp: 2032-05-08→ Common Stock (5,000 underlying) - Exercise/Conversion
Common Stock
2025-01-06$21.41/sh+5,000$107,050→ 33,222 total
Footnotes (4)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024.
- [F2]The price reported is a weighted-average price. The shares were sold at prices ranging from $84.23 to $85.17. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The price reported is a weighted-average price. The shares were sold at prices ranging from $85.235 to $86.23. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.
Documents
Issuer
Vaxcyte, Inc.
CIK 0001649094
Entity typeother
Related Parties
1- filerCIK 0001918033
Filing Metadata
- Form type
- 4
- Filed
- Jan 6, 7:00 PM ET
- Accepted
- Jan 7, 4:33 PM ET
- Size
- 12.5 KB